BeStock  
Stocks › Biotechnology › MLYS

Mineralys Therapeutics MLYS

US equityMarket cap rank #3034Biotechnology
$13.66 −$0.50 (-3.53%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $13.70 +0.29%
Open$13.81
Prev close$14.16
Day range$13.57 – $14.79
Volume1.35M
Market cap$1.21B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$60.09M-46.1% YoY
Net profit-$57.33M-55.2% YoY
Diluted EPS-$0.64-23.1% YoY
Free cash flow-$43.10M-49.3% YoY
Operating cash flow-$43.10M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-48.9MDec '24$-42.2MMar '25$-43.3MJun '25$-36.9MSep '25$-32.2MDec '25$-39.3MMar '26$-241.1MJun '26$-57.3MSep '26

Diluted EPS by quarter

-0.98Dec '24-0.79Mar '25-0.66Jun '25-0.52Sep '25-0.40Dec '25-0.47Mar '26-2.85Jun '26-0.64Sep '26

Free cash flow by quarter

$-66.8MDec '24$-45.5MMar '25$-30.2MJun '25$-28.9MSep '25$-37.9MDec '25$-39.5MMar '26$-32.6MJun '26$-43.1MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-68.5%
Return on assets-60.2%
Return on invested capital-61.7%
Current ratio11.83
Liabilities / assets20.1%
Cash & investments$624.67M
Total debt$98.27M
Net cash (debt)$526.40M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $60.09M $246.04M $45.34M $170.60M $38.28M
Selling and Admin Expenses $37.42M $24.66M $20.98M $38.60M $13.88M
-General & Admin Expense $37.42M $24.66M $20.98M $38.60M $13.88M
Research & Development $22.67M $221.38M $24.37M $132.01M $24.40M
Operating Profit -$60.09M -$246.04M -$45.34M -$170.60M -$38.28M
Net Non-Operating Interest Income (Expense) $2.76M $4.96M $6.00M $15.95M $6.05M
Non-Operating Interest Income $5.95M $4.96M $6.00M $15.95M $6.05M
Non-Operating Interest Expense $3.19M – – – –
Pretax Profit -$57.33M -$241.07M -$39.34M -$154.65M -$32.23M
Net Profit -$57.33M -$241.07M -$39.34M -$154.65M -$32.23M
Profit from Continuing Operations -$57.33M -$241.07M -$39.34M -$154.65M -$32.23M
Net Income to Parent Company -$57.33M -$241.07M -$39.34M -$154.65M -$32.23M
Net Income to Common Stockholders -$57.33M -$241.07M -$39.34M -$154.65M -$32.23M
Basic EPS -$0.64 -$2.85 -$0.47 -$2.29 -$0.40
Diluted EPS -$0.64 -$2.85 -$0.47 -$2.29 -$0.40
Other Income (Expense) – $13,000.00 $5,000.00 – –
Other Non-Operating Income (Expenses) – $13,000.00 $5,000.00 – –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $630.12M $667.85M $652.86M $661.81M $661.81M
Total Current Assets $627.99M $665.80M $652.47M $661.39M $661.39M
Cash and Cash Equivalents & Short-Term Investments $624.67M $661.41M $646.06M $656.64M $656.64M
-Cash and Cash Equivalents $101.27M $138.27M $112.78M $172.92M $172.92M
-Short Term Investments $523.40M $523.14M $533.28M $483.71M $483.71M
Other Current Assets $3.32M $4.39M $6.41M $4.75M $4.75M
Total Non-Current Assets $2.13M $2.05M $392,000.00 $420,000.00 $420,000.00
Net PPE $21,000.00 $27,000.00 $32,000.00 $38,000.00 $38,000.00
Other Non-Current Assets $2.11M $2.02M $360,000.00 $382,000.00 $382,000.00
Total Liabilities $126.35M $116.94M $14.72M $15.11M $15.11M
Total Current Liabilities $53.08M $19.32M $14.72M $15.11M $15.11M
Payables $738,000.00 $1.07M $1.12M $2.02M $2.02M
-Accounts Payable $738,000.00 $1.07M $1.12M $2.02M $2.02M
Current Accrued Expenses $20.47M $14.06M $11.29M $7.56M $7.56M
Short-Term Debt and Capital Lease Obligation $25.00M – – – –
-Current Debt $25.00M – – – –
Total Non-Current Liabilities $73.27M $97.62M $0.00 $0.00 $0.00
Long Term Debt and Capital Lease Obligation $73.27M – – – –
-Long Term Debt $73.27M – – – –
Total Equity $503.78M $550.92M $638.14M $646.69M $646.69M
Stockholders' Equity $503.78M $550.92M $638.14M $646.69M $646.69M
Capital Stock $9,000.00 $9,000.00 $8,000.00 $8,000.00 $8,000.00
-Common Stock $9,000.00 $9,000.00 $8,000.00 $8,000.00 $8,000.00
Additional Paid-In Capital $1.30B $1.29B $1.13B $1.10B $1.10B
Retained Earnings -$794.91M -$737.58M -$496.51M -$457.17M -$457.17M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$43.10M -$32.56M -$39.47M -$142.42M -$37.89M
Net cash flow from continuing operations -$43.10M -$32.56M -$39.47M -$142.42M -$37.89M
Net Income from Continuing Operations -$57.33M -$241.07M -$39.34M -$154.65M -$32.23M
Depreciation & Depletion & Amortization $6,000.00 $5,000.00 $6,000.00 $59,000.00 $13,000.00
Other Non-Cash Items -$4.15M $195.48M -$4.63M -$9.88M -$4.21M
Change in Working Capital $10.49M $5.67M -$2.06M $2.73M -$6.74M
-Change in Receivables -$153,000.00 $47,000.00 $289,000.00 -$166,000.00 -$181,000.00
-Change in Prepaid Assets $989,000.00 $1.96M -$1.95M $2.47M $1.57M
-Change in Payables and Accrued Expense $9.66M $3.67M -$402,000.00 $427,000.00 -$8.13M
Net cash flow from investing $4.70M -$185.22M -$44.94M -$389.75M -$103.49M
Net Cash Flow from Continuing Investing Activities $4.70M -$185.22M -$44.94M -$389.75M -$103.49M
Net Investment Purchase and Sale $4.70M $14.78M -$44.94M -$389.74M -$103.47M
Net Other Investing Changes $0.00 – – – –
Financing Cash Flow $1.40M $243.26M $24.27M $591.00M $96.70M
Net Cash Flow from Continuing Financing Activities $1.40M $243.26M $24.27M $591.00M $96.70M
Net Issuance Payments Of Debt $0.00 – – – –
Net Common Stock Issuance -$312,000.00 $143.90M $20.22M $578.36M $91.95M
Proceeds from Stock Option Exercised $2.34M $2.90M $4.06M $13.03M $5.06M
Net Other Financing Charges -$624,000.00 -$1.03M -$1,000.00 -$391,000.00 -$305,000.00
Ending Cash Balance $101.27M $138.27M $112.78M $172.92M $172.92M
Net Change in Cash -$37.00M $25.49M -$60.14M $58.83M -$44.68M
Beginning Cash Balance $138.27M $112.78M $172.92M $114.09M $217.60M
Free Cash Flow -$43.10M -$32.56M -$39.47M -$142.43M -$37.90M
Net PPE Purchase and Sale – – – -$15,000.00 -$15,000.00

Discussion

No comments yet — be the first to weigh in on MLYS.

Sign in to join the discussion.

Scroll to Top